ReviewKidney international reports2026
IgG4-Related Kidney Disease and IgG4-Related Retroperitoneal Fibrosis: An Update on Diagnosis and Treatment.
Review in Kidney international reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Renal involvement of IgG4-related disease (IgG4-RD), collectively termed IgG4-related kidney disease (IgG4-RKD), most commonly manifests as tubulointerstitial nephritis (TIN) but can also manifest as membranous glomerulonephritis (MGN) and acute interstitial nephritis (AIN) as a histologic subtype of IgG4-related TIN (IgG4-TIN). IgG4-related retroperitoneal fibrosis (IgG4-RPF) can cause obstructive kidney disease with or without active parenchymal IgG4-RKD. IgG4-RD is a clinicopathological diagnosis, requiring correlation of clinical, laboratory, radiological, and histological findings to identify features of IgG4-RD and rule out mimickers. Histopathologic features of IgG4-RD in tissue include a dense lymphoplasmacytic infiltrate rich in IgG4-positive plasma cells, typically accompanied by so-called "storiform" fibrosis. Important mimics of IgG4-RKD include infection, malignancy, antineutrophil cytoplasmic autoantibody (ANCA)-associated disease, idiopathic multicentric Castleman disease, Rosai-Dorfman-Destombes disease and Sjögren Disease (SjD). Mimickers of IgG4-RPF include lymphoma, Erdheim-Chester disease, and idiopathic RPF. IgG4-RKD and IgG4-RPF are responsive to the systemic therapies used for IgG4-RD in general. Corticosteroids are the traditional first line therapy; however, B cell-targeted therapies, including rituximab, inebilizumab, and obexelimab are more potent and less toxic than steroids. Further trials are currently being conducted on newer medications that target signaling pathways and immune cells involved in the pathogenesis of IgG4-RD. Early recognition and treatment are critical to prevent irreversible organ damage. This review summarizes the current understanding of the pathogenesis, clinical spectrum, diagnostic approach, and management strategies for IgG4-RD, IgG4-RKD, and IgG4-RPF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.